Neptune Technologies & Bioressources Inc (NTB.TO) 2.65 $NTB.TO
Shareholders of Neptune Technologies & Bioressources Inc. evaluate potential means to enhance shareholder value
CNW Group - Thu Apr 10, 4:18PM CDT
Mr. George Haywood, the largest shareholder of Neptune Technologies & Bioressources Inc. (Neptune) (TSX:NTB) announced today that he intends to initiate or participate in, alone or together with joint actors, all actions he deems necessary or advisable to enhance shareholder value in Neptune, including exploring various means to effect changes in the current management. A number of other Neptune shareholders, namely Messrs. Con Egan, Conor O'Driscoll and Fulvio Dobrich have agreed to support Mr. Haywood's initiatives to enhance shareholder value in Neptune. As a result of their support, Messrs. Egan, O'Driscoll and Dobrich may be considered "joint actors" of Mr. Haywood.
Neptune Announces Closing of CAD$2.5 Million Private Placement
GlobeNewswire - Fri Apr 04, 12:37PM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation"
(Nasdaq:NEPT) (TSX:NTB), announced today the closing of a private placement of CAD$2,503,320 of common shares of Neptune (the "Shares" at a price of CAD$2.76 per Share, resulting in a total of 907,000 Shares being issued today (the "Private Placement".
Neptune & Acasti Give Update on Patent Litigations With Enzymotec
GlobeNewswire - Tue Apr 01, 1:25PM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" (Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that they have been unable to conclude a final settlement agreement through mediation with Enzymotec Ltd. and Enzymotec USA, Inc. (collectively, "Enzymotec" that would resolve the International Trade Commission ("ITC" investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. Neptune and Acasti will now pursue Enzymotec through the ITC and the federal district court in Delaware.
Neptune Provides Update on Sherbrooke Plant
GlobeNewswire - Thu Mar 27, 6:45AM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation" (Nasdaq:NEPT) (TSX:NTB), announced today that reconstruction of its Sherbrooke, Quebec, Canada production facility will be completed April 7, 2014. Neptune is currently conducting equipment and safety related tests at the plant and employees are being trained. Preoperational testing will start early April 2014, with actual production commencing upon receipt of all outstanding permits.
NeuroBioPharm Extends Life of Warrants and Provides Other Corporate Updates
GlobeNewswire - Tue Mar 18, 1:14PM CDT
NeuroBioPharm Inc. ("NeuroBio" or the "Corporation", a Neptune Technologies & Bioressources Inc. subsidiary ("Neptune" (Nasdaq:NEPT) (TSX:NTB), announces that it has extended the life of its Series 2011-1 common share purchase warrants, initiated a royalty prepayment process with Neptune and appointed a new CFO.
Neptune Announces Closing of the Over-Allotment Option Associated with its Recently Completed Public Offering of Common Shares
PR Newswire - Thu Mar 06, 10:53AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" (NASDAQ.NEPT - TSX.NTB), announced today that the syndicate of underwriters led by of Euro Pacific Canada Inc. and Roth Capital Partners, as Joint Book-Running Managers, and National Securities Corporation, a wholly owned subsidiary of National Holdings, Inc. (NHLD) as Lead Manager, have exercised in full the over-allotment option to purchase an additional 1,500,000 common shares of Neptune at a price of US$2.50 per common share in connection with Neptune's previously announced public offering, completed on March 5, 2014. As a result of the exercise of the over-allotment option, Neptune received additional gross proceeds of US$3.75 million for total gross proceeds of US$28.75 million.
Neptune Announces Closing of US$25.0 Million Underwritten Offering of Common Shares
CNW Group - Wed Mar 05, 8:11AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" (NASDAQ.NEPT - TSX.NTB), a biotechnology company engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids, announced today the closing of its previously announced public offering of 10,000,000 common shares at US$2.50 per common share for gross proceeds of US$25.0 million. Euro Pacific Canada Inc. and Roth Capital Partners, LLC acted as Joint Book-Running Managers for the offering and National Securities Corporation, a wholly owned subsidiary of National Holdings, Inc. (NHLD), acted as Lead Manager.
Neptune Announces Pricing of US$25 Million Offering of Common Shares
GlobeNewswire - Fri Feb 28, 7:34AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company" (Nasdaq:NEPT) (TSX:NTB), a biotechnology company engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids, announced today that it has priced an underwritten public offering of 10,000,000 newly issued common shares at a public offering price of US$2.50 per share.
Neptune Announces Proposed Offering of Common Shares
CNW Group - Thu Feb 27, 3:59PM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company" (NASDAQ.NEPT) (TSX.NTB), a biotechnology company engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids, announced today that it has commenced an underwritten public offering of its common shares. The offering is being conducted in the United States pursuant to the Company's effective shelf registration statement filed with the U.S. Securities and Exchange Commission ("SEC" and in Canada pursuant to a final short form base shelf prospectus filed with the securities regulatory authorities in the Provinces of Québec, Ontario, Manitoba, Alberta and British Columbia. The number of common shares to be issued and the price of each common share will be determined at the time of pricing of the offering.
How Gunmen Killed 43 Students in Yobe
All Africa Global Media - Wed Feb 26, 1:32AM CST
Boko Haram cowards yesterday killed about 43 innocent students of the Federal Government College (FGC), Buni-Yadi in Gujba local government area of Yobe State.
Neptune Appoints John Moretz as Special Advisor and Nominee to Its Board of Directors
GlobeNewswire - Tue Feb 18, 6:50AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation" (Nasdaq:NEPT) (TSX:NTB) announces the appointment of John Moretz as special advisor to its Board of Directors. Mr. Moretz has also accepted the nomination for election to serve on the Corporation's Board of Directors at the next Annual Meeting to be held in 2014, subject to shareholders approval.
Neptune and Acasti Provide Update on Patent Litigations With Enzymotec
GlobeNewswire - Fri Feb 14, 8:52AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" (Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that a settlement agreement has not been finalized with Enzymotec Ltd. and Enzymotec USA, Inc. (collectively, "Enzymotec" that would resolve the International Trade Commission ("ITC" investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. The ITC investigation was instituted in early 2013 after Neptune and Acasti's filing of a complaint alleging infringement of Neptune's krill extract composition patents by Enzymotec and other industry players, including Aker BioMarine and Rimfrost USA, LLC. As previously announced, Neptune and Acasti have concluded settlement agreements with all other Respondents named in the ITC investigation, and motions to terminate the ITC investigation as to these companies have been granted. Only Enzymotec remains outstanding.
Acasti and Neptune Provide Update on Patent Litigations with Enzymotec
GlobeNewswire - Fri Feb 14, 8:40AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" (Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that a settlement agreement has not been finalized with Enzymotec Ltd. and Enzymotec USA, Inc. (collectively, "Enzymotec" that would resolve the International Trade Commission ("ITC" investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. The ITC investigation was instituted in early 2013 after Neptune and Acasti's filing of a complaint alleging infringement of Neptune's krill extract composition patents by Enzymotec and other industry players, including Aker BioMarine and Rimfrost USA, LLC. As previously announced, Neptune and Acasti have concluded settlement agreements with all other Respondents named in the ITC investigation, and motions to terminate the ITC investigation as to these companies have been granted. Only Enzymotec remains outstanding.
Neptune Reports Third Quarter Results and Provides Update on Action Plan to Resume Operations
GlobeNewswire - Tue Jan 14, 6:30AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation" (Nasdaq:NEPT) (TSX:NTB) announces its consolidated financial results for the three and nine-month periods ended November 30, 2013 and provides update on action plan to resume operations.
Neptune Receives New Food Raw Material Certification in China
GlobeNewswire - Thu Jan 09, 6:30AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation" (Nasdaq:NEPT) (TSX:NTB) announces that it has received "New Food Raw Material" certification in China. Neptune is now able to sell its krill oil nutraceutical products in China, including its premium krill oil, NKO, as well as its Eco krill oil "EKO(TM)". No quality or safety concerns were found by China's National Health and Family Planning Commission, which attests to the strength of Neptune's products.
Neptune to Hold Conference Call to Discuss Third Quarter Results
GlobeNewswire - Tue Jan 07, 6:30AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" (Nasdaq:NEPT) (TSX:NTB) will be holding a conference call on Wednesday January 15, at 9:00 am ET to present its results for the third quarter ended November 30, 2013. The Company will also be providing an update on the status of its previously disclosed action plan to resume operations and supply customers.
Neptune Appoints Jerald J. Wenker as Special Advisor and Nominee to Its Board of Directors
GlobeNewswire - Thu Dec 19, 6:30AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation" (Nasdaq:NEPT) (TSX:NTB) announces the appointment of Jerald J. Wenker as a special advisor to its Board of Directors. Mr. Wenker has also accepted the nomination for election to serve on the Corporation's Board of Directors at the next Annual Meeting to be held in 2014, subject to shareholder approval, including increasing the maximum number of Board of Directors to at least 7 members from 6 currently.
Shareholders of Neptune Technologies & Bioressources Inc. evaluate potential means to enhance shareholder value
CNW Group - Thu Apr 10, 4:18PM CDT
Mr. George Haywood, the largest shareholder of Neptune Technologies & Bioressources Inc. (Neptune) (TSX:NTB) announced today that he intends to initiate or participate in, alone or together with joint actors, all actions he deems necessary or advisable to enhance shareholder value in Neptune, including exploring various means to effect changes in the current management. A number of other Neptune shareholders, namely Messrs. Con Egan, Conor O'Driscoll and Fulvio Dobrich have agreed to support Mr. Haywood's initiatives to enhance shareholder value in Neptune. As a result of their support, Messrs. Egan, O'Driscoll and Dobrich may be considered "joint actors" of Mr. Haywood.
Neptune Announces Closing of CAD$2.5 Million Private Placement
GlobeNewswire - Fri Apr 04, 12:37PM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation"
(Nasdaq:NEPT) (TSX:NTB), announced today the closing of a private placement of CAD$2,503,320 of common shares of Neptune (the "Shares" at a price of CAD$2.76 per Share, resulting in a total of 907,000 Shares being issued today (the "Private Placement". Neptune & Acasti Give Update on Patent Litigations With Enzymotec
GlobeNewswire - Tue Apr 01, 1:25PM CDT
Neptune Technologies & Bioressources Inc. ("Neptune"
(Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that they have been unable to conclude a final settlement agreement through mediation with Enzymotec Ltd. and Enzymotec USA, Inc. (collectively, "Enzymotec" that would resolve the International Trade Commission ("ITC" investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. Neptune and Acasti will now pursue Enzymotec through the ITC and the federal district court in Delaware. Neptune Provides Update on Sherbrooke Plant
GlobeNewswire - Thu Mar 27, 6:45AM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation"
(Nasdaq:NEPT) (TSX:NTB), announced today that reconstruction of its Sherbrooke, Quebec, Canada production facility will be completed April 7, 2014. Neptune is currently conducting equipment and safety related tests at the plant and employees are being trained. Preoperational testing will start early April 2014, with actual production commencing upon receipt of all outstanding permits. NeuroBioPharm Extends Life of Warrants and Provides Other Corporate Updates
GlobeNewswire - Tue Mar 18, 1:14PM CDT
NeuroBioPharm Inc. ("NeuroBio" or the "Corporation"
, a Neptune Technologies & Bioressources Inc. subsidiary ("Neptune" (Nasdaq:NEPT) (TSX:NTB), announces that it has extended the life of its Series 2011-1 common share purchase warrants, initiated a royalty prepayment process with Neptune and appointed a new CFO. Neptune Announces Closing of the Over-Allotment Option Associated with its Recently Completed Public Offering of Common Shares
PR Newswire - Thu Mar 06, 10:53AM CST
Neptune Technologies & Bioressources Inc. ("Neptune"
(NASDAQ.NEPT - TSX.NTB), announced today that the syndicate of underwriters led by of Euro Pacific Canada Inc. and Roth Capital Partners, as Joint Book-Running Managers, and National Securities Corporation, a wholly owned subsidiary of National Holdings, Inc. (NHLD) as Lead Manager, have exercised in full the over-allotment option to purchase an additional 1,500,000 common shares of Neptune at a price of US$2.50 per common share in connection with Neptune's previously announced public offering, completed on March 5, 2014. As a result of the exercise of the over-allotment option, Neptune received additional gross proceeds of US$3.75 million for total gross proceeds of US$28.75 million. Neptune Announces Closing of US$25.0 Million Underwritten Offering of Common Shares
CNW Group - Wed Mar 05, 8:11AM CST
Neptune Technologies & Bioressources Inc. ("Neptune"
(NASDAQ.NEPT - TSX.NTB), a biotechnology company engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids, announced today the closing of its previously announced public offering of 10,000,000 common shares at US$2.50 per common share for gross proceeds of US$25.0 million. Euro Pacific Canada Inc. and Roth Capital Partners, LLC acted as Joint Book-Running Managers for the offering and National Securities Corporation, a wholly owned subsidiary of National Holdings, Inc. (NHLD), acted as Lead Manager. Neptune Announces Pricing of US$25 Million Offering of Common Shares
GlobeNewswire - Fri Feb 28, 7:34AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company"
(Nasdaq:NEPT) (TSX:NTB), a biotechnology company engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids, announced today that it has priced an underwritten public offering of 10,000,000 newly issued common shares at a public offering price of US$2.50 per share. Neptune Announces Proposed Offering of Common Shares
CNW Group - Thu Feb 27, 3:59PM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company"
(NASDAQ.NEPT) (TSX.NTB), a biotechnology company engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids, announced today that it has commenced an underwritten public offering of its common shares. The offering is being conducted in the United States pursuant to the Company's effective shelf registration statement filed with the U.S. Securities and Exchange Commission ("SEC" and in Canada pursuant to a final short form base shelf prospectus filed with the securities regulatory authorities in the Provinces of Québec, Ontario, Manitoba, Alberta and British Columbia. The number of common shares to be issued and the price of each common share will be determined at the time of pricing of the offering. How Gunmen Killed 43 Students in Yobe
All Africa Global Media - Wed Feb 26, 1:32AM CST
Boko Haram cowards yesterday killed about 43 innocent students of the Federal Government College (FGC), Buni-Yadi in Gujba local government area of Yobe State.
Neptune Appoints John Moretz as Special Advisor and Nominee to Its Board of Directors
GlobeNewswire - Tue Feb 18, 6:50AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation"
(Nasdaq:NEPT) (TSX:NTB) announces the appointment of John Moretz as special advisor to its Board of Directors. Mr. Moretz has also accepted the nomination for election to serve on the Corporation's Board of Directors at the next Annual Meeting to be held in 2014, subject to shareholders approval. Neptune and Acasti Provide Update on Patent Litigations With Enzymotec
GlobeNewswire - Fri Feb 14, 8:52AM CST
Neptune Technologies & Bioressources Inc. ("Neptune"
(Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that a settlement agreement has not been finalized with Enzymotec Ltd. and Enzymotec USA, Inc. (collectively, "Enzymotec" that would resolve the International Trade Commission ("ITC" investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. The ITC investigation was instituted in early 2013 after Neptune and Acasti's filing of a complaint alleging infringement of Neptune's krill extract composition patents by Enzymotec and other industry players, including Aker BioMarine and Rimfrost USA, LLC. As previously announced, Neptune and Acasti have concluded settlement agreements with all other Respondents named in the ITC investigation, and motions to terminate the ITC investigation as to these companies have been granted. Only Enzymotec remains outstanding. Acasti and Neptune Provide Update on Patent Litigations with Enzymotec
GlobeNewswire - Fri Feb 14, 8:40AM CST
Neptune Technologies & Bioressources Inc. ("Neptune"
(Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that a settlement agreement has not been finalized with Enzymotec Ltd. and Enzymotec USA, Inc. (collectively, "Enzymotec" that would resolve the International Trade Commission ("ITC" investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. The ITC investigation was instituted in early 2013 after Neptune and Acasti's filing of a complaint alleging infringement of Neptune's krill extract composition patents by Enzymotec and other industry players, including Aker BioMarine and Rimfrost USA, LLC. As previously announced, Neptune and Acasti have concluded settlement agreements with all other Respondents named in the ITC investigation, and motions to terminate the ITC investigation as to these companies have been granted. Only Enzymotec remains outstanding. Neptune Reports Third Quarter Results and Provides Update on Action Plan to Resume Operations
GlobeNewswire - Tue Jan 14, 6:30AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation"
(Nasdaq:NEPT) (TSX:NTB) announces its consolidated financial results for the three and nine-month periods ended November 30, 2013 and provides update on action plan to resume operations. Neptune Receives New Food Raw Material Certification in China
GlobeNewswire - Thu Jan 09, 6:30AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation"
(Nasdaq:NEPT) (TSX:NTB) announces that it has received "New Food Raw Material" certification in China. Neptune is now able to sell its krill oil nutraceutical products in China, including its premium krill oil, NKO, as well as its Eco krill oil "EKO(TM)". No quality or safety concerns were found by China's National Health and Family Planning Commission, which attests to the strength of Neptune's products. Neptune to Hold Conference Call to Discuss Third Quarter Results
GlobeNewswire - Tue Jan 07, 6:30AM CST
Neptune Technologies & Bioressources Inc. ("Neptune"
(Nasdaq:NEPT) (TSX:NTB) will be holding a conference call on Wednesday January 15, at 9:00 am ET to present its results for the third quarter ended November 30, 2013. The Company will also be providing an update on the status of its previously disclosed action plan to resume operations and supply customers. Neptune Appoints Jerald J. Wenker as Special Advisor and Nominee to Its Board of Directors
GlobeNewswire - Thu Dec 19, 6:30AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation"
(Nasdaq:NEPT) (TSX:NTB) announces the appointment of Jerald J. Wenker as a special advisor to its Board of Directors. Mr. Wenker has also accepted the nomination for election to serve on the Corporation's Board of Directors at the next Annual Meeting to be held in 2014, subject to shareholder approval, including increasing the maximum number of Board of Directors to at least 7 members from 6 currently. 
